Altered cellular and humoral immunity to varicella-zoster virus in patients with autoimmune diseases

Arthritis and Rheumatology

Volumn 66, Issue 11, 2014, Pages 3122-3128

  Rondaan, Christien ^a   De Haan, Aalzen ^a   Horst, Gerda ^a   Hempel, J Cordelia ^a   Van Leer, Coretta ^a   Bos, Nicolaas A ^a   Van Assen, Sander ^a   Bijl, Marc ^b   Westra, Johanna ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b MARTINI HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYFLUORESCEIN; GAMMA INTERFERON; GLYCOPROTEIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE PREDISPOSITION; DYE DILUTION CURVE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STIMULATION; SYSTEMIC LUPUS ERYTHEMATOSUS; VARICELLA ZOSTER VIRUS; WEGENER GRANULOMATOSIS; AUTOIMMUNE DISEASE; BLOOD; CASE CONTROL STUDY; HERPES ZOSTER; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR; VIROLOGY;

ADULT; AUTOIMMUNE DISEASES; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CROSS-SECTIONAL STUDIES; DISEASE SUSCEPTIBILITY; FEMALE; GRANULOMATOSIS WITH POLYANGIITIS; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84920052630     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38804     Document Type: Article

References (33)

1. Gershon AA, Gershon MD, Breuer J, Levin MJ, Oaklander AL, Griffiths PD,. Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J Clin Virol 2010; 48 Suppl 1: S2-7.
2. Heininger U, Seward JF,. Varicella. Lancet 2006; 368: 1365-76.
3. Bond D, Mooney J,. A literature review regarding the management of varicella-zoster virus. Musculoskeletal Care 2010; 8: 118-22.
4. Drolet M, Brisson M, Schmader KE, Levin MJ, Johnson R, Oxman MN, et al., The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. CMAJ 2010; 182: 1731-6.
5. Drolet M, Levin MJ, Schmader KE, Johnson R, Oxman MN, Patrick D, et al., Employment related productivity loss associated with herpes zoster and postherpetic neuralgia: a 6-month prospective study. Vaccine 2012; 30: 2047-50.
6. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al., A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352: 2271-84.
7. Yawn BP, Saddier P, Wollan PC, St. Sauver JL, Kurland MJ, Sy LS,. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007; 82: 1341-9.
8. Van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, et al., EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011; 70: 414-22.
9. Rahier JF, Moutschen M, van Gompel A, van Ranst M, Louis E, Segaert S, et al., Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology (Oxford) 2010; 49: 1815-27.
10. Doria A, Zampieri S, Sarzi-Puttini P,. Exploring the complex relationships between infections and autoimmunity. Autoimmun Rev 2008; 8: 89-91.
11. Cush JJ, Calabrese L, Kavanaugh A,. Herpes zoster (shingles) vaccine guidelines for immunosuppressed patients. URL: http://www.rheumatology.org/publications/hotline/2008-08-01-shingles.asp. American College of Rheumatology. August 1, 2008.
12. Chen HH, Chen YM, Chen TJ, Lan JL, Lin CH, Chen DY,. Risk of herpes zoster in patients with systemic lupus erythematosus: a three-year follow-up study using a nationwide population-based cohort. Clinics (Sao Paulo) 2011; 66: 1177-82.
13. Kimberlin DW, Whitley RJ,. Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med 2007; 356: 1338-43.
14. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630-40.
15. Barbosa CM, Terreri MT, Rosario PO, de Moraes-Pinto MI, Silva CA, Hilario MO,. Immune response and tolerability of varicella vaccine in children and adolescents with systemic lupus erythematosus previously exposed to varicella-zoster virus. Clin Exp Rheumatol 2012; 30: 791-8.
16. Harpaz R, Ortega-Sanchez IR, Seward JF, and the Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008; 57: 1-30.
17. Zhang J, Delzell E, Xie F, Baddley JW, Spettell C, McMahan RM, et al., The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study. Arthritis Res Ther 2011; 13: R174.
18. Zhang J, Xie F, Delzell E, Chen L, Winthrop KL, Lewis JD, et al., Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA 2012; 308: 43-9.
19. Cogman AR, Chakravarty EF,. The case for Zostavax vaccination in systemic lupus erythematosus. Vaccine 2013; 31: 3640-3.
20. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al., 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 625-39.
21. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al., The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
22. Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, et al., The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990; 33: 1101-7.
23. Fauci AS, Moutsopoulos HM,. Polyclonally triggered B cells in the peripheral blood and bone marrow of normal individuals and in patients with systemic lupus erythematosus and primary Sjögren's syndrome. Arthritis Rheum 1981; 24: 577-83.
24. Blaese RM, Grayson J, Steinberg AD,. Increased immunoglobulin-secreting cells in the blood of patients with active systemic lupus erythematosus. Am J Med 1980; 69: 345-50.
25. Nagasawa K, Yamauchi Y, Tada Y, Kusaba T, Niho Y, Yoshikawa H,. High incidence of herpes zoster in patients with systemic lupus erythematosus: an immunological analysis. Ann Rheum Dis 1990; 49: 630-3.
26. Hurd ER, Dowdle W, Casey H, Ziff M,. Virus antibody levels in systemic lupus erythematosus. Arthritis Rheum 1972; 15: 267-74.
27. Draborg AH, Duus K, Houen G,. Epstein-Barr virus and systemic lupus erythematosus. Clin Dev Immunol 2012; 2012: 370516.
28. Cohrs RJ, Mehta SK, Schmid DS, Gilden DH, Pierson DL,. Asymptomatic reactivation and shed of infectious varicella zoster virus in astronauts. J Med Virol 2008; 80: 1116-22.
29. Uchakin PN, Parish DC, Dane FC, Uchakina ON, Scheetz AP, Agarwal NK, et al., Fatigue in medical residents leads to reactivation of herpes virus latency. Interdiscip Perspect Infect Dis 2011; 2011: 571340.
30. Nagel MA, Choe A, Cohrs RJ, Traktinskiy I, Sorensen K, Mehta SK, et al., Persistence of varicella zoster virus DNA in saliva after herpes zoster. J Infect Dis 2011; 204: 820-4.
31. Sayeeda A, Al Arfaj H, Khalil N, Al-Arfaj AS,. Herpes zoster infections in SLE in a university hospital in Saudi Arabia: risk factors and outcomes. Autoimmune Dis 2010; 2010: 174891.
32. Borba EF, Ribeiro AC, Martin P, Costa LP, Guedes LK, Bonfa E,. Incidence, risk factors, and outcome of herpes zoster in systemic lupus erythematosus. J Clin Rheumatol 2010; 16: 119-22.
33. Wung PK, Holbrook JT, Hoffman GS, Tibbs AK, Specks U, Min YI, et al., Herpes zoster in immunocompromised patients: incidence, timing, and risk factors. Am J Med 2005; 118: 1416.